Products with Antimalaric bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4391 | Lapachol |
| Lapachol shows both antimicrobial, trypanocidal and antiviral activities, it also shows antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Probiotics are capable of converting Lapachol into the most effective cytotoxic compound against a breast cancer cell line. | |
| BCN4420 | 11(13)-Dehydroivaxillin |
| 1. 11(13)-Dehydroivaxillin possesses a promising antiplasmodial activity, which can be exploited in malaria therapy. | |
| BCN4489 | Walsuronoid B |
| 1. Walsuronoid B shows weak antimalarial activity. | |
| BCN4607 | Akuammigine |
| 1. Akuammidine shows a preference for mu-opioid binding sites with Ki values of 0.6, 2.4 and 8.6 microM at mu-, delta- and kappa-opioid binding sites, respectively; the agonist actions of akuammidine in the mouse-isolated vas deferens were antagonised by naloxone and the mu-opioid receptor selective antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) confirming an action at mu-opioid receptors. 2. Akuammigine competitively antagonizes the effect of noradrenaline on postsynaptic alpha-adrenoceptors, yielding pA2 values of 4.68. 3. Akuammigine has in vitro antimalarial activity. | |
| BCN4745 | Goniotriol |
| 1. Goniotriol exhibits antiplasmodial activity against Plasmodium falciparum (IC50=2.6 microg/mL). 2. Goniotriol shows antimycobacterial activity against Mycobacterium tuberculosis (MIC =100 microg/mL). 3. Goniotriol shows cytotoxicity against cancer cells, KB, BC1, NCI-H187, and MCF-7 with IC(50) ranging from 0.4 to 22.7 microg/mL. | |
